Description
EnocitABIneisaderivativeofcytarabinethatactsasanucleosideanalogofcytosine.Enocitabineistheapro-drugofAra-Candexhibitsanticancerchemotherapeuticandantiviralactivities.Likeothernucleosideanalogs,enocitabineisincorporatedintoDNA,preventingchainelongationandcellgrowth.Enocitabineisclinicallyusedinsomecountriesandisundergoingclinicaltrialsinothersasapotentialtreatmentforleukemiasandlymphomassuchasacutemyelogenousleukemia(AML).Enocitabinealsoinhibitsreplicationandgrowthofcytomegalovirus(CMV).
References
ItoY,WakitaA,TakadaS,etal.Phase1trialofgemtuzumabozogamicinincombinationwithenocitabineanddaunorubicinforelderlypatientswithrelapsedorrefractoryacutemyeloidleukemia:JapanAdultLeukemiaStudyGroup(JALSG)-GML208study.IntJHematol.2012Oct;96(4):485-91.PMID:22956429.
HamadaA,KawaguchiT,NakanoM.Clinicalpharmacokineticsofcytarabineformulations.ClinPharmacokinet.2002;41(10):705-18.PMID:12162758.
NakamuraK,EizuruY,KumuraK,etal.AntiviraleffectofantileukemicdrugsN4-behenoyl-1-beta-D-arabinofuranosylcytosine(BH-AC)and2,2"-anhydro-1-beta-D-arabinofuranosylcytosine(cyclo-C)againsthumancytomegalovirus.JMedVirol.1990Jun;31(2):141-7.PMID:1696958.
MaeharaY,KusumotoT,KusumotoH,etal.Invitrosensitivityofvarioushumantumorsto1-beta-D-arabinofuranosylcytosineandN4-behenoyl-1-beta-D-arabinofuranosylcytosine.Chemotherapy.1989;35(3):181-6.PMID:2766858.
HigashigawaM,OchiaiH,OhkuboT,etal.IncorporationofN4-behenoyl-1-beta-D-arabinofuranosylcytosineintoDNAas1-beta-D-arabinofuranosylcytosine.MedOncolTumorPharmacother.1988;5(4):265-71.PMID:2848163.
